Loading stock data…
TSHA
$6.82+0.01 (+0.15%)
Market ClosedLast close May 11
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Taysha Gene Therapies, Inc. in the Healthcare sector is trading at $6.82. The stock is currently near its 52-week high of $7.30, remaining 52.2% above its 200-day moving average. Technical signals show neutral RSI of 63 and bearish MACD signal, explaining why TSHA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.82
Potential Upside
5%
Whystock Fair Value$7.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company prima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.55%
Volume
Today's trading volume
1.72M
Recent News
Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best US Stocks Under $5 to Buy. On May 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) with a price target of $17 on the stock. This update comes after the company reported results for the first quarter of 2026. Taysha […]
Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent Volatility
Taysha Gene Therapies (TSHA) has drawn investor attention after recent trading, with the stock showing sharp moves over the past month and past 3 months, prompting closer scrutiny of its risk and potential. See our latest analysis for Taysha Gene Therapies. That recent volatility sits on top of very strong longer term momentum, with a 30 day share price return of 45.95%, a 90 day share price return of 44.69% and a 1 year total shareholder return above 200%. This comes even though the latest...
Taysha Gene Therapies, Inc. Q1 2026 Earnings Call Summary
Moby summary of Taysha Gene Therapies, Inc.'s Q1 2026 earnings call
Taysha Gene Therapies Q1 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) executives highlighted regulatory progress, ongoing clinical enrollment, and manufacturing preparations for its Rett syndrome gene therapy candidate TSHA-102 during the company’s first-quarter 2026 earnings call, while also reporting a wider year-over-year net los
Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?
If you are wondering whether Taysha Gene Therapies at US$6.46 is starting to look expensive or still has room to run, the key question is what the current price implies about the company’s underlying value. The stock has been flat over the last week, while the 30 day return is 58.7%, the year to date return is 23.0% and the 1 year return is 258.9%, with a very large 3 year return and a 72.6% decline over 5 years highlighting how quickly sentiment can shift. Recent coverage has focused on...